Last kr7.15 DKK
Change Today 0.00 / 0.00%
Volume 13.9K
EXQ On Other Exchanges
Symbol
Exchange
Copenhagen
As of 9:35 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

exiqon a/s (EXQ) Snapshot

Open
kr7.40
Previous Close
kr7.15
Day High
kr7.40
Day Low
kr7.15
52 Week High
03/3/14 - kr9.10
52 Week Low
10/3/14 - kr4.40
Market Cap
263.6M
Average Volume 10 Days
31.1K
EPS TTM
kr-0.07
Shares Outstanding
36.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXIQON A/S (EXQ)

Related News

No related news articles were found.

exiqon a/s (EXQ) Related Businessweek News

No Related Businessweek News Found

exiqon a/s (EXQ) Details

Exiqon A/S provides life science research products worldwide. It operates through two segments, Life Sciences and Diagnostics. The company’s products serve as a platform for the development of molecular diagnostic tests. It develops molecular diagnostic tests in collaboration with pharmaceutical and diagnostic companies. The company’s products include miRCURY RNA isolation kits; microRNA Array system, a system for global microRNA expression profiling; microRNA qPCR system, which enables microRNA expression profiling; microRNA detection probes that are used for the ultra-sensitive, and detection of microRNAs by Northern blot analysis and in situ hybridization; and microRNA inhibitor and target site blockers for functional analysis. It also offers microarrays capture probes for expression analysis of splice variants, small RNAs, and mRNA; qPCR assays for mRNA and ncRNA; RNA detection probes for in situ hybridization and Northern blot; and longRNA GapmeR, which are antisense oligonucleotides used for the inhibition of mRNA and lncRNA function. In addition, the company provides oligonucleotides and microarray capture probes to detect single nucleotide polymorphism; FISH probes to detect chromosomal DNA sequences; custom LNA oligonucleotides; LNA phosphoramidites for the synthesis of LNA containing oligonucleotides; and A2-quencher phosphoramidite, a dark quencher for real-time PCR probes. Further, it offers RNA isolation services for the sample types, including exosome isolation, blood derived serum, plasma and other bio-fluids, clinical FFPE and fresh frozen tissues, and cell lines; MicroRNA array and profiling services; microRNA and Small RNA sequencing services; microRNA in situ hybridization screening services; and custom pharma services, such as biomarker discovery, validation experiments, and others. The company markets its research products through direct sales, distributors, and the Web. Exiqon A/S was founded in 1995 and is headquartered in Vedbæk, Denmark.

91 Employees
Last Reported Date: 01/30/15
Founded in 1995

exiqon a/s (EXQ) Top Compensated Officers

Chief Executive Officer, President and Member...
Total Annual Compensation: kr3.3M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: kr2.2M
Compensation as of Fiscal Year 2014.

exiqon a/s (EXQ) Key Developments

Exiqon A/S Announces Group and Parent Earnings Results for the Fourth Quarter and Group Earnings Results Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year 2015

Exiqon A/S announced Group and parent earnings results for the fourth quarter and Group earnings results full year ended December 31, 2014. For the quarter, on group basis, revenue was DKK 34.4 million against DKK 28.7 million a year ago. LBITDA was DKK 1.1 million against DKK 2.6 million a year ago. Net loss was DKK 3.6 million against DKK 3.2 million a year ago. LPS was DKK 0.10 against DKK 0.09 a year ago. Fourth quarter revenue increased 20% driven by record products and services sales.  For the year, on group basis, revenue was DKK 132.4 million against DKK 123.6 million a year ago. EBITDA was DKK 3.1 million against LBITDA of DKK 4.1 million a year ago. Net loss was DKK 2.8 million against DKK 10.7 million a year ago. LPS was DKK 0.08 against DKK 0.29 a year ago. Full year revenue increased 7% and products and services sales increased 6% driven by 32% organic growth in services sales. Full year LBIT improved 65% to DKK 3.1 million from LBIT of DKK 8.8 million a year ago. Cash flow used in operating activities was DKK 2.4 million compared to cash flow from operating activities of DKK 3.2 million a year ago. Acquisition of intangible assets was DKK 2.382 million compared to DKK 2.616 million a year ago. Acquisition of property, plant and equipment was DKK 2.595 million compared to DKK 2.022 million a year ago. Operating loss was DKK 3.082 million compared to DKK 8.780 million a year ago. Loss before tax was DKK 5.983 million compared to DKK 11.508 million a year ago. For the year, on parent basis, revenue was DKK 111,195,000 against DKK 102,243,000 a year ago. Operating loss(LBIT) was DKK 3,908,000 against DKK 9,720,000 a year ago. Loss before tax was DKK 7,017,000 against DKK 12,436,000 a year ago. Loss for the year was DKK 3,327,000 against DKK 11,186,000 a year ago. Cash flow used in operating activities was DKK 5,706,000 against cash flows from operating activities of DKK 3,095,000 a year ago. Acquisition of intangible assets was DKK 2.382 million compared to DKK 2.616 million a year ago. Acquisition of property, plant and equipment was DKK 2.529 million compared to DKK 1.957 million a year ago. In 2015, Exiqon expects total revenue between DKK 150-160 million and EBITDA around DKK 5-10 million.

Exiqon A/S to Report Fiscal Year 2014 Results on Jan 30, 2015

Exiqon A/S announced that they will report fiscal year 2014 results on Jan 30, 2015

Exiqon A/S Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Revenue Guidance for the Year 2014

Exiqon A/S reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of DKK 34,825,000 against DKK 29,800,000 a year ago. EBITDA was DKK 2,522,000 against DKK 84,000 a year ago. Operating profit (EBIT) was DKK 823,000 against operating loss of DKK 1,019,000 a year ago. Profit for the period was DKK 1,312,000 against operating loss of DKK 1,699,000 a year ago. Diluted and basic EPS was DKK 0.04 against basic and diluted LPS of DKK 0.05 a year ago. Profit before tax was DKK 456,000 against loss before tax was DKK 1,588,000 a year ago. For the nine months, the company reported revenue of DKK 98,018,000 against DKK 94,856,000 a year ago. EBITDA was DKK 4,230,000 against LBITDA of DKK 1,504,000 a year ago. Operating loss was DKK 233,000 against DKK 5,092,000 a year ago. Profit for the period was DKK 862,000 against operating loss of DKK 7,447,000 a year ago. Cash flows used in operating activities was DKK 966,000 against DKK 1,079,000 a year ago. Acquisition of intangible assets and property, plant and equipment was DKK 4,322,000 against DKK 1,559,000 a year ago. Diluted and basic EPS was DKK 0.02 against basic and diluted LPS of DKK 0.20 a year ago. Loss before tax was DKK 1,784,000 against DKK 7,071,000 a year ago. The company expects revenues around DKK 135 million and EBITDA around DKK 5 million in 2014. The outlook for 2014 is based on an average USD/DKK exchange rate of DKK 5.50.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXQ:DC kr7.15 DKK 0.00

EXQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $11.70 USD -0.08
Fluidigm Corp $42.43 USD -1.74
Luminex Corp $15.70 USD -0.39
NanoString Technologies Inc $11.13 USD -0.07
WaferGen Bio-systems Inc $4.85 USD -0.10
View Industry Companies
 

Industry Analysis

EXQ

Industry Average

Valuation EXQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXIQON A/S, please visit www.exiqon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.